At 2.5% CAGR, the Middle East & Africa Transdermal Medical Patch Market is projected to be worth US$ 239.75 million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the Middle East & Africa transdermal medical patch market was valued at US$ 212.17 million in 2023 and is expected to reach US$ 239.75 million by 2028, registering a CAGR of 2.5% from 2023 to 2028. Advancements in smart patches and three-dimensional (3D)-printed patches and increasing strategic initiatives are the critical factors attributed to the Middle East & Africa transdermal medical patch market expansion.                    

The transdermal drug administration route is novel and one of the reliable means of sustained drug delivery. With significant research being carried out in this field and increasing interest of researchers in this form of drug delivery, the number of transdermal patches reaching the marketplace is expected to rise sharply. Transdermal patches have attracted attention for decades and were used to deliver drugs such as nicotine, fentanyl, nitroglycerin, and clonidine to treat various diseases or conditions. Recently, these patches have been explored to deliver biologics in various applications. For example, smart patches are equipped with sensors and other technologies to monitor patient conditions and adjust drug delivery accordingly.

According to a study titled "A smart hydrogel patch with high transparency, adhesiveness, and hemostasis for all-round treatment and glucose monitoring of diabetic foot ulcers," published in 2022, scientists have developed an intelligent patch to monitor and treat diabetic foot ulcers. This system is fabricated from conductive hydrogel patches with an ultra-high transparency polymer network. Researchers are using 3D printing technology to create customized transdermal patches (e.g., a 3D-printed patch for wound healing) tailored as per patient's needs. In a study by Jang et al. titled "Gelatin Methacrylate Hydrogel for Tissue Engineering Applications—A Review on Material Modifications," published in 2022, gelatin methacrylate (GelMA) was tested as a viable option with tunable physical properties. GelMA hydrogel incorporating a vascular endothelial growth factor (VEGF)-mimicking peptide was successfully printed using a 3D bio-printer due to the hydrogel inks' shear-thinning properties.

In this study, two liquid monomers—polyethylene glycol diacrylate (PEGDA) and vinylpyrrolidone (VP)—in different proportions were used to improve the mechanical strength, polymerization rate, and swelling rate of the final polymer. Optimal drug loading on the resin indicated that AHP-3 remained stable throughout the manufacturing process and had no effect on the physical properties of the final polymer. Using a 3D scanned facial model, a personalized patch was designed in computer-aided design software and fabricated in optimized resin using a digital light processing 3D printer.

Thus, the adoption of 3D printing technology and smart patches will likely be a prevalent trend in the market over the coming years.  

On the contrary, recalls of transdermal medical patches due to drug failure hurdles the growth of Middle East & Africa transdermal medical patch market. 

Based on type, the Middle East & Africa transdermal medical patch market is segmented into single-layer drug in-adhesive, multi-layer drug in-adhesive, reservoir, vapor patch and matrix. The matrix segment held 35.0% market share in Middle East & Africa transdermal medical patch market in 2023, amassing US$ 74.26 million. It is projected to garner US$ 86.59 million by 2028 to expand at 3.1% CAGR during 2023–2028.

Based on application, the Middle East & Africa transdermal medical patch market is segmented into neurologic conditions, pain management, nicotine cessation, cardiovascular disorders, hormonal therapy, and others. The pain management segment held 32.7% market share in Middle East & Africa transdermal medical patch market in 2023, amassing US$ 69.35 million. It is projected to garner US$ 79.67 million by 2028 to expand at 2.8% CAGR during 2023–2028.

Based on distribution channels, the Middle East & Africa transdermal medical patch market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 43.7% market share in Middle East & Africa transdermal medical patch market in2023, amassing US$ 92.79 million. It is projected to garner US$ 102.12 million by 2028 to expand at 1.9% CAGR during 2023–2028

Based on country, the Middle East & Africa transdermal medical patch market has been categorized into Saudi Arabia, South Africa, the UAE, and Rest of Middle East & Africa.  Our regional analysis states that Saudi Arabia captured 33.2% market share in 2023. It was assessed at US$ 70.41 million in 2023 and is likely to hit US$ 81.91million by 2028, exhibiting a CAGR of 3.1% during the forecast period.     

Key players dominating the Middle East & Africa transdermal medical patch market are Boehringer Ingelheim International GmbH; Endo International Inc; Hisamitsu Pharmaceutical Co Inc; Johnsons and Johnsons; Medline Industries LP; Novartis AG; Teva Pharmaceutical Industries Ltd.; and Viatris Inc among others.   

• In Jan 2021, Notice regarding Obtaining Approval of Partial Change of Approved Matters of “Mohrus Paps XR 120 mg and 240 mg”, Transdermal Analgesic Anti-Inflammatory Patches
• In Jan 2020, Notification of approval for manufacturing and marketing approval of OABLOK PATCH in Thailand

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com